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ABSTRACT
Class I phosphatidylinositol 3-kinases (PI3Ks) are frequently activated in T-cell 
acute lymphoblastic leukemia (T-ALL), mainly due to the loss of PTEN function. 
Therefore, targeting PI3Ks is a promising innovative approach for T-ALL treatment, 
however at present no definitive evidence indicated which is the better therapeutic 
strategy between pan or selective isoform inhibition, as all the four catalytic subunits 
might participate in leukemogenesis. Here, we demonstrated that in both PTEN 
deleted and PTEN non deleted T-ALL cell lines, PI3K pan-inhibition exerted the 
highest cytotoxic effects when compared to both selective isoform inhibition or dual 
p110γ/δ inhibition. Intriguingly, the dual p110γ/δ inhibitor IPI-145 was effective in 
Loucy cells, which are representative of early T-precursor (ETP)-ALL, a T-ALL subtype 
associated with a poor outcome. PTEN gene deletion did not confer a peculiar reliance 
of T-ALL cells on PI3K activity for their proliferation/survival, as PTEN was inactivated 
in PTEN non deleted cells, due to posttranslational mechanisms. PI3K pan-inhibition 
suppressed Akt activation and induced caspase-independent apoptosis. We further 
demonstrated that in some T-ALL cell lines, autophagy could exert a protective role 
against PI3K inhibition. Our findings strongly support clinical application of class I 
PI3K pan-inhibitors in T-ALL treatment, with the possible exception of ETP-ALL cases.
INTRODUCTION
Class I phosphatidylinositol 3-kinases (PI3Ks) 
comprise members of a conserved family of heterodimeric 
intracellular lipid kinases involved in crucial aspects 
of cell growth and survival through phosphorylation 
of phosphatidylinositol-4, 5-bisphosphate (PIP2) to 
phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) which 
acts as an intracellular second messenger by binding with 
high affinity to pleckstrin homology (PH) domains in target 
molecules [1]. Among the binding partners, there are the 
serine-threonine protein kinases Akt and phosphoinositide-
dependent kinase 1 (PDK1). Recruitment to the plasma 
membrane brings these two proteins in close proximity, 
allowing PDK1 to phosphorylate and activate Akt which 
in turn phosphorylates target proteins affecting cell 
growth, cell cycle progression, and cell survival [2]. 
The activation of the PI3K pathway is controlled by 
the 3′-phosphate lipid phosphatase PTEN (phosphatase 
and tensin homolog deleted on chromosome 10) which 
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prevents the accumulation of PIP3 converting it back into 
PIP2 [3]. Members of class I PI3Ks are further divided 
into two subfamilies, class IA consisting of a p85α, 
p85β or p55γ regulatory subunit and a p110α, p110β or 
p110δ catalytic subunit, and class IB consisting of a p101 
regulatory subunit and a p110γ catalytic subunit, which 
receive activation inputs from tyrosine kinases or GTPase 
signaling, respectively [1]. Unlike the ubiquitous p110α 
and p110β, p110δ and p110γ isoforms are preferentially 
expressed in leucocytes [4]. PI3K regulates many steps 
in the development, differentiation, and activation 
of T-cells. p110δ and p110γ are widely involved in 
thymocyte development and differentiation, especially 
during β-selection and transition between immature 
DP (double positive) and mature SP (single positive) 
thymocytes [4, 5]. Nevertheless, PI3K subunits seem to 
have a redundant role, and other isoforms could markedly 
impact T cell development [6]. Due to the crucial role of 
PI3Ks in regulating cell cycle, metabolism, and survival, 
the PI3K signaling cascade is one of the most frequently 
altered pathways in human cancers [7–9], and different 
compounds targeting members of the PI3K network have 
been developed and entered clinical trials [1].
T-cell acute lymphoblastic leukemia (T-ALL) 
is an aggressive neoplastic disorder of T-lymphocytes 
characterized by a poor clinical outcome, especially 
for relapsed patients [10]. In T-ALL, the PI3K pathway 
is frequently up-regulated mainly due to alterations, 
including phosphorylation, oxidation and gene deletion/
mutation, that affect PTEN function [11–13]. Deregulation 
of the PI3K signaling pathway confers a proliferative 
advantage to malignant cells and might contribute 
to drug-resistance mechanisms. Therefore, targeting 
PI3K pathway may be an attractive novel therapeutic 
intervention in T-ALL. However, which class of agents 
among isoform-specific or pan-inhibitors can achieve the 
greater efficacy is still an open question. Indeed, if on 
the one hand the use of selective inhibitors might reduce 
systemic toxicity, on the other hand pan-inhibitors could 
display increased efficacy. In relation to this issue, it has 
been documented that PTEN-null T-ALL cells exclusively 
relied on p110γ and p110δ, as their combined absence 
decreased the tumor incidence in a PTEN-deficient 
mouse model, suggesting their predominant roles in 
sustaining malignant transformation [14]. Moreover, in 
human T-ALL cells devoid of PTEN, pharmacological 
blockade of both p110γ and p110δ impacted on tumor 
cell proliferation and survival, supporting the relevance of 
these isoforms as therapeutic targets for T-ALL treatment 
[14]. On the contrary, a more recent study highlighted 
the importance of blocking all class I PI3K isoforms to 
efficiently inhibit cell proliferation in PTEN deficient 
T-ALL cell lines [15]. However, in T-ALL patients PTEN 
genomic alterations are low frequency events, as PTEN 
gene deletions and mutations predicted to cause protein 
truncation occur collectively in about 10% of T-ALL cases 
[11, 12, 16]. In T-ALL, the predominant mechanisms 
responsible for PTEN functional inactivation and 
constitutive PI3K pathway activation are phosphorylation 
and/or oxidation, which have been detected at level 
above of control thymocytes in 91.7% and 81.3% of 
primary T-ALL samples, respectively [11]. Therefore, 
in the present study we aimed to further investigate the 
effects of PI3K inhibition in both PTEN deleted and non 
deleted T-ALL cell lines. For this purpose, we employed 
a pharmacological approach to compare the effects of 
selective and PI3K pan-inhibition. We used compounds 
which specifically target p110α, p110β, p110γ, and 
p110δ PI3K catalytic subunits, along with dual p110γ/
p110δ and pan-PI3K inhibitors, and we evaluated their 
effects on leukemic cell proliferation and survival. Our 
results demonstrated that PI3K pan-inhibition exerted 
the most powerful effects on leukemic cell proliferation 
and survival in all the tested cell lines, irrespectively 
of PTEN status, with the possible exception of Loucy 
cells. Therefore, our findings strongly support clinical 
application of class I PI3K pan-inhibitors rather than dual 
γ/δ or single-isoform inhibitors for the treatment of the 
major part of T-ALL patients.
RESULTS
In vitro assessment of PI3K inhibitor effects on 
cell viability
In order to establish the role of the different 
PI3K catalytic subunits in supporting leukemic cells 
proliferation and survival, we exploited a pharmacological 
approach by using selective inhibitors, dual p110γ/δ, or 
pan-inhibitors. The pan-inhibitor BKM-120 has been 
evaluated in both preclinical hematologic and solid 
tumor models [17, 18] and phase I clinical trials [19–21], 
whereas ZSTK-474 [22–24] and PIK-90 [15] efficacy has 
been assessed only in preclinical models. To specifically 
inhibit p110α, p110β, p110δ, and p110γ we employed 
A-66, TGX-221, CAL-101, and AS-605240, respectively, 
whose selectivity has been reported elsewhere [14, 15, 25], 
and that, at least in several instances, have shown 
effectiveness in hematological malignancies [26]. Because 
of the prominent role of p110δ and p110γ isoforms in 
T-lymphocytes [5], effects of the γ/δ dual inhibitor  IPI-145, 
as well as of a combination consisting of CAL-101 and 
AS-605240 were also evaluated. Several clinical trials 
have shown the efficacy of CAL-101, which displayed 
substantial anti-leukemic effects as single agent in both 
chronic lymphocytic leukemia (CLL) [27] and indolent 
non-Hodgkin lymphoma (iNHL) [28] patients with an 
acceptable safety profile. On this basis, the dual inhibitor 
IPI-145, initially developed as an anti-inflammatory drug 
[29], has been tested in phase I clinical trials enrolling 
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relapsed/refractory lymphoma [30] or advanced CLL 
[31]. Results suggested that the drug is safe and effective 
and encouraged further evaluation of IPI-145 as a targeted 
drug also in newly diagnosed CLL patients.
Cells were cultured with increasing concentrations 
of the drugs for 48 h followed by metabolic activity 
assessment by MTT assay (Fig. 1A and 1C). In both 
PTEN deleted (Jurkat and Loucy) and PTEN non deleted 
(DND-41 and ALL-SIL) cells, growth rate decreased 
after treatment with BKM-120 and ZSTK-474 with IC50 
values ranging between 1.05–2.34 μM for BKM-120 
and 0.99–3.39 μM for ZSTK-474. Conversely, PIK-90 
only mildly affected T-ALL cell line viability, with the 
exception of Loucy cells (IC50 0.096 μM). As expected, 
selective inhibition of p110α, p110β, p110γ, and p110δ 
isoforms resulted ineffective, with IC50 values not attained 
at the tested concentrations. We further investigated 
the effectiveness of combining p110δ and p110γ 
inhibitors, by treating T-ALL cell lines with CAL-101 
and AS-605240 at a fixed ratio (1:1). As shown in Fig. 
1B and 1D, the inhibitors resulted in a strong (CI < 0.3) 
to moderate (CI < 0.9) synergism in ALL-SIL, Loucy, 
and Jurkat cells at concentrations above 1 μM, whereas 
in DND-41 cells the drug combination did not exert a 
synergistic but rather an antagonistic (at 1 and 2 μM) 
or additive (at 4 and 8 μM) effect. Nevertheless, IC50 
values achieved by the combined treatment were much 
higher compared to those of pan-inhibitors (Fig. 1C). 
Interestingly, the dual p110γ/δ inhibitor IPI-145 was 
effective only in Loucy cells. Overall, PI3K isoform 
pan-inhibition was much more efficient in affecting 
T-ALL cell viability when compared to specific as well 
Figure 1: Inhibition of all the PI3K catalytic isoforms exerts the strongest effects on T-ALL cell line viability. A and B. 
MTT analysis of PTEN deleted (Jurkat, Loucy) and non deleted (ALL-SIL, DND-41) T-ALL cell lines treated for 48 h with increasing 
concentration of PI3K inhibitors (BKM-120, ZSTK-474, and PIK-90 are pan-inhibitors; A-66, TGX-221, AS-605240, CAL-101 are 
selective inhibitors of p110α, p110β, p110γ, and p110δ, respectively; IPI-145 is a dual inhibitor of p110γ/δ). (B) Effects of the combination 
consisting of AS-605240 and CAL-101 on cell viability. C. IC50 values obtained through MTT assays after 48 h treatment with increasing 
concentrations of PI3K inhibitors. Three replicates per tested concentration and at least two independent experiments were performed 
(bars, SD). D. Analysis of the effects of the AS-605240 (p110γ inhibitor) and CAL-101 (p110δ inhibitor) combination, which resulted 
synergistic in Jurkat, Loucy, and ALL-SIL cells (CIs 0.1–0.9). In DND-41 cells, CIs values > 2 indicate an antagonistic effect, whereas 
CIs > 1 are additive. (CI: combination index; Fa: Fraction affected).
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as dual p110γ/δ inhibition. Based on these results, we 
selected ZSTK-474 as pan-inhibitor and we used the 
concentration of 5 μM for the following experiments to 
simplify comparison of the results obtained with the other 
inhibitors.
PI3K pan-inhibition affects cell proliferation in a 
PTEN independent fashion
We investigated in more detail the effects of 
the PI3K pathway inhibition on cell proliferation, by 
analyzing the long-term cell growth over 3 days post-
treatment with the drugs. The pan-inhibitor ZSTK-474 
significantly impaired cell proliferation in all the cell lines, 
independently from PTEN status, whereas p110α and 
p110β inhibition produced negligible effects (Fig. 2A). 
Specific and dual inhibition of p110γ and p110δ isoforms 
displayed an irregular pattern. Jurkat and DND-41 cell 
proliferation was unaffected, conversely in Loucy and 
ALL-SIL cells either p110δ inhibition or dual p110γ/δ 
inhibition significantly impaired cell growth (Fig. 2A). 
Compared to untreated controls, ZSTK-474 markedly 
slowed down the doubling time in Loucy, DND-41, and 
ALL-SIL cells, whereas a negative doubling time was 
estimated in Jurkat cells, suggesting cell death induction 
(Fig. 2C). Importantly, in Loucy cells, the only cell 
line responsive to IPI-145, proliferation was impaired 
already at 0.5 μM after treatment with this dual inhibitor 
(Fig. 2B and 2C).
To ascertain whether the observed effects of 
ZSTK-474 on cell growth rate were due to a proliferative 
impairment, we also evaluated by flow cytometry the 
expression of the proliferation marker Ki-67, a nuclear 
antigen which is a well established marker of cell 
Figure 2: PI3K pan-inhibition impairs proliferation in T-ALL cell lines. Growth curves of T-ALL cell lines treated with 5 μM 
of PI3K selective and pan-inhibitors A. or with increasing concentration (0.5, 1 and 5 μM) of the dual inhibitor IPI-145 B. Viable cells were 
counted before treatment (0 h), and after 16, 24, 40, 48, 64 and 72 h of treatment. Cell growth was calculated as the percentage of viable cells 
compared to that at T 0 h. Four independent counts for each time point and two independent experiments for each cell line were performed 
(bars, SD). C. Doubling time obtained from the cell count analysis. Increase in doubling time indicates a proliferation impairment. The 
negative doubling time observed in Jurkat cells indicates cell death induction. Asterisks indicate statistically significant differences with 
respect to untreated cells (*p < 0.05; **p < 0.01; ***p < 0.001). D. Flow cytrometric analysis of the proliferation marker Ki-67. Cells were 
treated with 5 μM of the pan inhibitor ZSTK-474 for 72 h. Upper panel: control cells (untreated). Lower panels: treated cells.
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proliferation [32]. In agreement with the growth analyses, 
Ki-67 decreased broadly in all the cell lines after 72 h 
treatment with the pan-inhibitor ZSTK-474 (Fig. 2D). 
These results demonstrated that overall PI3K pan-
inhibition impaired cell proliferation more efficiently than 
dual p110γ/δ inhibition.
Anti-proliferative effects of PI3K inhibitors are 
independent from total PIP3 level reduction
Firstly, we investigated cell lines with regard 
to PI3K isoforms and PTEN expression. As shown in 
Fig. 3A, the catalytic subunits p110α, −β, −γ and −δ 
Figure 3: Expression of PI3K catalytic subunits and PTEN in T-ALL cell lines, and effects of PI3K inhibition on total 
PIP3 levels. A. Western blot analysis. Cells were cultured for 6 h with the different inhibitors, as indicated, and western blot analysis 
was then performed. PTEN non deleted cell lines express abundantly PTEN protein, however PTEN is phosphorylated at Ser380, which 
is an inhibitory site of its lipid phosphatase activity. B. Flow cytomety quantification of the second messenger PIP3 in cells treated with 
5 μM of PI3K inhibitors for 6 h. Bars, SD. Asterisks indicate statistically significant differences with respect to untreated cells (*p < 0.05;  
**p < 0.01; ***p < 0.001).
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were expressed in control as well as treated samples to 
a similar extent. As expected, PTEN protein was absent 
in Jurkat and Loucy cells, but abundantly expressed and 
unaffected by drug treatments in ALL-SIL and DND-41 
cells. Nevertheless, in both of these cell lines, PTEN was 
phosphorylated at Ser380, which is a marker of PTEN 
posttranslational inactivation by CK2 and consequent 
PI3K pathway activation [12, 33].
To evaluate the impact of the inhibitors on PI3K 
activity, total PIP3 levels were then quantified by flow 
cytometry [11]. Pan-inhibition was able to induce a 
significant reduction of PIP3 in all cell lines after a 6 h 
treatment with the drugs. Regarding the isoform selective 
inhibitors, all the compounds induced a decrease in 
PIP3 levels, suggesting that each PI3K catalytic isoform 
could contribute to PIP2 phosphorylation in T-ALL cells 
(Fig. 3B). However, there were differences related to the 
cell type. While in Jurkat cells all the inhibitors drastically 
decreased PIP3, in the other cell lines a significant decrease 
in PIP3 could be detected only with some of the inhibitors 
(CAL-101 in DND-41; A-66, AS-605240 and combination 
of AS-605240 plus CAL-101 in ALL-SIL; A-66, CAL-101 
and combination of AS-605240 plus CAL-101 in Loucy 
cells). Moreover, PIP3 decreased in a concentration-
dependent fashion in Loucy cells treated with the dual 
p110γ/δ inhibitor IPI-145 (0.5, 1 and 5 μM; Fig. 3B). 
These observations suggested a peculiar addiction to 
PI3K isoforms of the different cell lines with regard to 
PIP2 phosphorylation, suggesting a potential influence of 
cellular-specific mechanisms in PIP3 generation. However, 
PIP3 reduction did not fully correlate with the observed 
anti-proliferative effects induced by the inhibitors.
Taken together, these data demonstrated that each 
isoform can sustain PIP3 synthesis in T-ALL cells, but 
PIP3 total cellular amount was not fully related to cellular 
proliferation.
PI3K pan-inhibition impairs Akt-mediated 
signaling
We next examined the effects of the different 
inhibitors on signaling downstream of PI3K. One of the 
major PI3K targets is the serine/threonine kinase Akt, 
which is recruited to the plasma membrane through direct 
interaction with PIP3 and subsequent phosphorylation 
on Thr308 by PDK1 and Ser473 by mTORC2 for full 
activation [7]. In all cell lines, selective p110α, −β or −γ 
inhibition was unable to reduce Akt phosphorylation at 
Thr308, whereas both p110δ and dual p110γ/δ inhibition 
induced a comparable decrease, suggesting a major role 
for the p110δ isoform in the phosphorylation of this Akt 
amino acidic residue (Fig. 4A). Conversely,  pan-inhibition 
Figure 4: PI3K pan-inhibition impacts on the PI3K/Akt/mTOR pathway. Cells were cultured for 6 h A and C. or 24 h B.  
in the presence of 5 μM of the different PI3K inhibitors, as indicated, and western blot analysis was then performed. The pan-inhibitor 
ZSTK-474 and the combination of p110γ and p110δ inhibitors (AS-605240 and CAL-101) induced the dephosphorylation of the main  
PI3K downstream targets Akt, P70S6K , and S6RP (A and B) but only ZSTK-474 decreased both the phosphorylated residues of Akt, 
Thr308 and Ser473. Only in Loucy cells, the dual p110γ/δ inhibitor IPI-145 exerted a concentration-dependent activity on PI3K downstream 
targets. (C) The phosphorylation of PDK1, PKCα and PKCβII was not modulated by inhibition of PI3K. Thirty μg of protein was blotted to 
each lane. Antibody to β-Actin served as a loading control. Molecular weights are indicated at right. Ctr, untreated cells.
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exerted the strongest effect on Akt activation, with a 
complete abrogation of phosphorylation at Thr308. 
Most importantly, only pan-inhibition induced a significant 
reduction of Akt phosphorylated at Ser473, either after 
6 h (Jurkat, Loucy, and DND-41 cells; Fig. 4A) or 24 h 
(ALL-SIL cells; Fig. 4B) treatment, suggesting mTORC2 
inhibition. Analysis of Akt downstream targets showed a 
congruent pattern of dephosphorylation, with a decrease 
in p-P70S6K both at Thr421/Ser424 (auto-inhibitory 
domain) and at Thr389 (mTORC1 phosphorylation site), 
and p-S6RP at Ser235/236, after pan- or, to a lesser 
extent, dual p110γ/δ inhibition (Fig. 4A). In all cases, total 
protein levels were unaffected. Consistently with the cell 
viability and proliferation analyses, only in the Loucy cell 
line down-modulation of p110γ/δ activity with the dual 
inhibitor IPI-145 was as effective as PI3K pan-inhibition 
and displayed a concentration-dependent trend (Fig. 4A).
To assess if other targets beyond Akt could be 
affected by PI3K inhibition, we further investigated PDK1 
and some of its downstream targets, PKCα and PKCβ 
(Fig. 4C). We observed that neither selective, nor dual 
or pan-inhibitors reduced phosphorylated levels of PKC 
isoforms [34]. Therefore, block of PI3K activity mainly 
inhibited Akt and its downstream targets.
Anti-proliferative activity of PI3K pan-inhibition 
acts through cell cycle arrest and caspase-
independent apoptosis
Since PI3K/Akt signaling controls different cellular 
pathways, we examined the inhibitor effects on cell cycle 
and induction of apoptosis. Interestingly, cell cycle was 
affected in all the cell lines following pan-inhibition 
(ZSTK-474 treatment for 48 h) (Fig. 5A). Flow cytometric 
analysis documented an accumulation of cells in the G0/G1  
phase of the cell cycle and a consequent decrease of cells 
in the S or G2/M phases, as previously reported [23], 
which reached a statistical significance in ALL-SIL and 
DND-41 cells. Moreover, in Jurkat, Loucy, and ALL-
SIL cells, ZSTK-474 increased the subG1 cell fraction, 
which comprises death cells. Less dramatic effects were 
observed with the other inhibitors, which affected only 
ALL-SIL and Loucy cells. In particular, the combination of 
AS-605240 and CAL-101 altered cell cycle phase 
distribution in Loucy cells, by increasing the G0/G1 fraction. 
However, the dual γ/δ inhibitor IPI-145 had no effects.
Annexin V-FITC/PI analysis confirmed a significant 
increase in apoptotic cells following treatment with ZSTK-
474 for 48 h in all the cell lines, whereas dual p110γ/δ 
inhibition had limited effects, inducing a significant cell 
death only in the Loucy cell line (Fig. 5B).
Moreover, western blot analysis demonstrated the 
absence of cleaved effector caspase 3 both at 24 and 48 h 
of treatment with the inhibitors (Fig. 5C and data not shown) 
suggesting that caspases did not contribute to cell death. 
To formally prove that, we treated T-ALL cell lines with 
ZSTK-474 in the presence or absence of the pan-
caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone (z-VAD-fmk). As presented in Fig. 5D, 
cell death induced by pan-inhibition was not affected by 
caspase inhibition.
Overall, these results demonstrated that PI3K 
inhibition caused cell cycle arrest in G0/G1 cell phase but 
only pan-inhibition was able to efficiently induce cell 
death with a caspase-independent mechanism.
Autophagy is a protective mechanism against 
PI3K pan-inhibition
Autophagy is a homeostatic cellular process which 
regulates protein and organelle turnover through their 
lysosomal destruction [35]. However, autophagy also 
executes cell death, and autophagic cell death is one of the 
better recognized caspase-independent programmed cell 
death mechanisms [36]. To analyze possible autophagy 
induction, we investigated the expression of LC3B 
I/II, a recognized autophagy marker [37]. Western blot 
analysis demonstrated a marked increase in LC3B II, 
the lipidated form of the protein which is bound to the 
autophagosome membranes, in Loucy, ALL-SIL and 
DND-41 cells, especially following 24 h ZSTK-474 
treatment, whereas no changes were observed in Jurkat 
cells (Fig. 6A). Because PI3K pan-inhibition with ZTK-
474 treatment induced a considerable percentage of cell 
death in Jurkat cells compared to the other cell lines, we 
supposed a protective role of autophagy in this context. 
To test our hypothesis, we inhibited autophagy with 
the early-stage autophagy inhibitor 3-methyladenine 
(3-MA) and subsequently evaluated cell death induced 
by treatment with ZSTK-474. The results demonstrated 
that 3-MA increased the cytotoxic effect of pan PI3K 
inhibition, as the percentage of Annexin V/PI positive cells 
was significantly higher in Loucy, ALL-SIL, and DND-41 
cells compared to that of samples treated with ZSTK-474 
alone (Fig. 6B). On the contrary, in Jurkat cells, where 
pan-inhibition did not induce LC3B lipidation, inhibition 
of autophagy did not increase cytotoxicity (Fig. 6B). To 
ascertain whether the different behavior between Jurkat 
cells and the other cell lines was related to a different 
modulation of autophagy-related genes, a screening for 
gene expression was performed using a quantitative real-
time PCR assay which interrogates 82 genes related to the 
autophagic pathway (Tab. 1 and Fig. 6C). Unsupervised 
hierarchical clustering showed similarities in autophagy 
gene expression in each paired cell line (untreated and 
treated samples) (Fig. 6C), although untreated Loucy cells 
showed a basal higher expression of these genes compared 
to the other cell lines. Moreover, no differentially clustered 
transcripts were observed in Jurkat cells, despite the fact 
that this cell line did not activate the autophagy process 
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following PI3K pan-inhibition. Nevertheless, we further 
investigated the modulation of autophagy in more detail, by 
comparing for each cell line untreated and treated samples 
and assessing for each gene the fold change, expressed as 
2−∆∆Ct. A 24 h treatment with ZSTK-474 had limited effects 
on autophagy at a transcriptional level, as the majority of 
genes resulted expressed equally to the control (2−∆∆Ct = 1) 
or slightly reduced (2−∆∆Ct < 1), especially in Loucy cells 
(Fig. 6C). Nevertheless, in some instances we observed 
a > 2 fold increase both in components of the autophagic 
machinery and in genes involved in autophagy regulation 
(Tab. 2 and Fig. 6D). In particular, in Loucy, ALL-SIL, 
and DND-41 cells, PI3K pan-inhibition increased the 
expression of DRAM1, GABARAPL1, GABARAPL2, 
WIPI1, MAP1LC3B, and ATG16L2, all involved in 
autophagic vesicle nucleation and expansion, as well 
as increased expression of genes involved in autophagy 
induction and regulation (INS, PIK3C) or prosurvival 
genes (BCL2, EIF2AK3). In contrast, in Jurkat cells, 
pan-inhibition had limited effects on autophagy-related 
gene induction, as the only upregulated gene was ULK1. 
However, we observed a > 2 fold change in expression of 
the tumor suppressor gene CDKN1B, as well as in CTSS 
(cathepsin S) gene. Interestingly, low levels of cathepsin S 
or its pharmacological inhibition have been related to the 
induction of autophagy in cancer cells [38, 39].
These results demonstrated that PI3K pan-inhibition 
could induce autophagy which plays a protective role in 
Figure 5: PI3K pan-inhibition affects cell cycle progression and induces caspase-independent cell death. A. Flow 
cytometry analysis of PI-stained cells treated with 5 μM of the different PI3K inhibitors (as indicated) for 48 h. The pan-inhibitor ZSTK-
474 increased the subG1 and/or the G0/G1 cell fraction, with the consequent decrease of the other cell cycle phases, whereas the dual p110γ/δ 
exerted limited effects on the cell cycle progression. The dual inhibitor IPI-145 did not perturb the cell cycle of the Loucy cell line. B. Flow 
cytometric analysis of Annexin V-FITC/PI–stained T-ALL cells treated with 5 μM of the different PI3K inhibitors for 48 h documented 
a significant increase in the cell death fraction with respect to untreated cells only after PI3K pan-inhibition. However, the dual inhibitor 
IPI-145 exerted a concentration-dependent pro-apoptotic effect on Loucy cells. C. Western blotting documented that PI3K inhibition did 
not induce caspase-3 activation. Thirty μg of protein was blotted to each lane. Antibody to β-Actin served as a loading control. Molecular 
weights are indicated at right. D. T-ALL cells were treated with 5 μM ZSTK-474 for 48 h with or without the pan-caspase inhibitor z-VAD-
fmk (50 μM) and the cell death fraction was assessed using Annexin V-FITC/PI staining. Caspase inhibition did not reduce cytotoxicity. 
Results are the mean of three different experiments ± SD. Asterisks indicate statistically significant differences with respect to untreated 
cells (*p < 0.05; **p < 0.01; ***p < 0.001).
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Figure 6: PI3K pan-inhibition induces autophagy which plays a protective role. A. Western blotting demonstrated autophagy 
activation in Loucy, ALL-SIL, and DND-41 cell lines in response to PI3K inhibition. Thirty μg of protein was blotted to each lane. Antibody 
to β-Actin served as a loading control. Molecular weights are indicated at right. B. T-ALL cells were treated with 5 μM ZSTK-474 for 48 h 
with or without the autophagy inhibitor 3-MA (200 μM) and cell death fraction was assessed by Annexin V-FITC/PI staining. Autophagy 
inhibition significantly increased cell death in Loucy, ALL-SIL, and DND-41 cell lines, whereas it did not affect Jurkat cells. Results are the 
mean of three different experiments ± SD. Asterisks indicate statistically significant differences with respect to untreated cells (*p < 0.05;  
**p < 0.01; ***p < 0.001). C. Real-time PCR expression profiling of 82 autophagy-related genes in T-ALL cell lines untreated (Ctr) or 
treated for 24 h with 5 μM ZSTK-474 were visualized using an unsupervised heat map. Data are presented as 2−∆Ct (∆Ct = Ct target gene – Ct RLP0).  
D. Histograms represent the relative gene expression of several autophagy-related genes in T-ALL cells treated with ZSTK-474 and 
compared to untreated paired sample. Data are presented as 2−∆∆Ct (∆∆Ct = ∆Ct treated sample – ∆Ct Ctr sample). When fold change values are = 1, 
the regulation in treated samples is equal to the paired control sample. When fold change values are > 1 or < 1, the autophagy-related genes 
are up- or down-regulated, respectively, compared to untreated samples.
Table 1: Autophagy-related genes analyzed using real-time PCR microarrays
Autophagy Machinery Components
AMBRA1, ATG10, ATG12, ATG16L1, ATG16L2, ATG3, ATG4A, ATG4B, ATG4C, ATG4D, ATG5, ATG7, ATG9A, BECN1, 
DRAM1, GABARAP, GABARAPL1, GABARAPL2, IRGM, LAMP1, MAP1LC3A, MAP1LC3B, NPC1, RAB24, RGS19, 
ULK1, ULK2, WIPI1
Regulation of Autophagy
AKT1, APP, BAD, BAK1, BAX, BCL2, BCL2L1, BID, BNIP3, CASP3, CASP8, CDKN1B, CDKN2A, CLN3, CTSB, 
CTSD, CTSS, CXCR4, DAPK1, DRAM2, EIF2AK3, EIF4G1, ESR1, FADD, FAS, GAA, HDAC1, HDAC6, HGS, HSPA8, 
HSP90AA1, HTT, IFNG, IGF1, INS, MAPK14, MAPK8, MTOR, NFKB1, PIK3CG, PIK3C3, PIK3R4, PTEN, RB1, 
RPS6KB1, SNCA, SQSTM1, TGFB1, TGM2, TMEM74, TNF, TNFSF10, TP53, UVRAG
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T-ALL cells, and suggested that autophagy activation in 
the different T-ALL cell lines might be dependent on a 
different gene expression regulation.
DISCUSSION
PI3K signaling is often deregulated in malignancies 
and contribute to the oncogenic process. The mechanisms 
responsible for class I PI3Ks up-regulation diverge 
among the distinct tumors. For example, gain of function 
mutations in PIK3CA, that encodes the catalytic subunit 
p110α, have been detected in a wide variety of human 
solid cancers [40], whereas p110δ is implicated in cancers 
derived from B lymphoid cells [41, 42]. Recently, the 
oncogenic potential of p110β [43] has emerged in breast 
[44] and prostate cancers [45]. Tumor cells addiction to 
the activity of specific class I PI3K isoforms had led to 
the development of therapies based on the application 
of selective PI3K inhibitors which target the catalytic 
subunits [46]. In T-ALL, PI3K signaling up-regulation 
has been found in nearly 90% of cases [11] and targeting 
PI3K is an attractive novel strategy to treat these patients. 
Nevertheless, at present is still controversial the role 
carried out by the different PI3K catalytic subunits in 
T-ALL and, therefore, which might be the most useful 
therapeutic strategy. It is well established that both 
p110γ and p110δ, enriched in leucocytes, are involved 
in thymocyte development [5]. The catalytic subunits 
Table 2: Autophagy-related genes up-regulated after PI3K pan-inhibition
Autophagy Machinery Components
DRAM1 DNA-damage regulated autophagy modulator 1 Lysosomal modulator of autophagy induced by p53
GABARAPL1 GABA(A) receptor-associated protein like 1 essential for autophagosome maturation
GABARAPL2 GABA(A) receptor-associated protein-like 2 essential for autophagosome maturation
MAP1LC3B Microtubule-associated protein 1 light chain 3 beta involved in formation of autophagosomes
ATG16L2 Autophagy-related 16-like 2 May play a role in autophagy during membrane biogenesis
ULK1 unc-51 like autophagy activating kinase 1 Regulate the formation of autophagophores (upstream PIK3C)
WIPI1 WD repeat domain, phosphoinositide interacting 1
Required for autophagosome formation 
(downstream ULK1 and PIK3C)
Regulation of Autophagy
INS Insulin Peptide hormone
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3
May positively modulate autophagydisplacing 
Bcl-2 from the Bcl-2/Beclin 1 complex
TNF Tumor necrosis factor Cytokine
ESR1 Estrogen receptor 1 Regulate autophagy core proteins
BCL2 B-cell CLL/lymphoma 2 Promote cellular survival
EIF2AK3 Eukaryotic translation initiation factor 2-alpha kinase 3
Repress global protein synthesis. Critical effector 
of unfolded protein response (UPR)
IFNG Interferon gamma Cytokine
PIK3C3 Phosphatidylinositol 3-kinase, catalytic subunit type 3
Involved in initiation and maturation of 
autophagosomes
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27Kip1) Cell cycle regulator. Its degradation is required for G1 cell phase progression
TP53 Tumor protein p53 Tumor suppressor
CTSS Cathepsin S Cysteine lysosomal protease involved in 
autophagic flux regulation
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p110α and p110β are ubiquitously expressed so that it is 
extremely difficult to dissect their role in lymphocytes, due 
to the embryonic lethality induced by loss of either p110α 
or p110β [47]. However, there is a complex interplay 
between the class I PI3K members, as inhibition or loss of 
a specific isoform might be compensated by the others in 
interleukin-3-dependent mouse hematopoietic cells [48]. 
Moreover, recent findings have highlighted that in solid 
tumors inhibition of a single PI3K isoform (either α or β) 
could be compensated by reactivation of another isoform 
[49, 50].
Recently, Subramanian et al., by employing the dual 
γ/δ inhibitor CAL-130, proposed the predominant role of 
p110γ and p110δ in PTEN deleted T-ALL, suggesting 
the possibility to target this malignancy by inhibiting 
specifically these isoforms [14]. It should be underscored, 
however, that after this initial report, no other papers 
dealing with the effects of CAL-130 have been published. 
In contrast, a more recent work contradicted these results, 
showing higher cytotoxic effects of the PI3K pan-inhibitor, 
PIK-90, in PTEN deleted T-ALL cell lines [15]. However, 
both of these studies did not take into account that PTEN 
deletions or inactivating gene mutations are relatively 
rare in primary T-ALL patients, whereas posttranslational 
inactivation of PTEN is a much more frequent event 
[11]. In light of those contradictory findings, we have 
used isoform-selective, pan- and dual p110γ/δ inhibitors 
to compare their effects in both PTEN deleted and non 
deleted T-ALL cell lines. Our results demonstrated that 
blockage of all the class I PI3K catalytic isoforms exerted 
a greater anti-cancer effect compared to dual p110γ/δ 
inhibition, as exemplified by the lower IC50 attained in 
all the cell lines, whereas isoform-selective inhibition 
produced negligible effects. Among the three PI3K pan-
inhibitors we tested, PIK-90 was effective only in Loucy 
cells, highlighting that chemical structure might affect 
drug efficacy. Moreover, only Loucy cells were sensitive 
to the dual γ/δ inhibitor, IPI-145. The peculiar sensitivity 
of Loucy cells to PI3K pathway inhibition is remarkable, 
as this cell line displays a transcriptional signature 
similar to that of early T-precursor (ETP)-ALL, a T-ALL 
subtype associated with an extremely poor prognosis 
[51]. Therefore, it will be very critical to test this drug on 
primary cells derived from patients with ETP-ALL.
Moreover, we did not observe differences between 
PTEN deleted and non deleted cell lines. Indeed, despite 
the expression of PTEN protein, we confirmed that in 
non deleted cells, PTEN was phosphorylated at Ser380 
and thus inactivated. This observation underlines the 
importance of assessing PI3K pathway activation in 
T-ALL patients rather than just PTEN deletions/mutations, 
for a better evaluation of patient outcome or possible 
therapeutic intervention with pathway modulators. We 
also observed a decrease in total PIP3 levels following 
inhibition of each PI3K catalytic subunit, suggesting 
that all the PI3K isoforms contribute to its synthesis in 
T-ALL cells. However, inhibitor effects on PIP3 levels did 
not fully correlate with their cytotoxicity. This apparent 
contradiction might be due to the presence of different 
PIP3 pools which mediate specific cellular processes, 
so that reduction of total PIP3 could not fully reflect the 
impairment of cell proliferation/survival mechanisms 
[52]. Moreover, it is emerging that PI3K could control 
other downstream targets in cancer cells, including 
serum/glucocorticoid-regulated kinase 3 (SGK3), in a 
manner which is independent from PIP3, but dependent on 
phosphatidylinositol 3-phosphate [53].
Only PI3K pan-inhibition switched off Akt 
signaling, as demonstrated by the reduction or complete 
abrogation of both Thr308 and Ser473 p-Akt levels. It 
has been previously reported that a limited PI3K activity 
is sufficient to support cell survival and proliferation 
and, consequently, complete PI3K inhibition is required 
to induce cell death [48]. Consistent with that, in spite 
of changes in cell cycle progression, we observed a 
significant cell death induction almost exclusively after 
PI3K pan-inhibition, with the exception of Loucy cells 
where the dual inhibition of p110γ/δ was also effective. 
Importantly, we demonstrated that, at least in the case of 
ZSTK-474, the mechanisms involved in cell death are 
independent of caspase activity as a pan-caspase inhibitor 
did not reduce cell death.
Numerous studies have highlighted the existence 
of various types of programmed cell death besides 
apoptosis, including autophagy, an important catabolic 
mechanism which can play both a pro-survival or pro-
death role [54]. Importantly, PI3K and autophagy 
pathways are tightly related, as mTORC1 suppress 
autophagy by inhibiting ULK1, and the transcription 
factor FoxO3, which is inhibited by active Akt, regulates 
a number of autophagy-related genes, including LC3, 
GABARAPL1, BNIP3, PIK3C3, and ULK1 [35, 55, 56]. 
Our findings demonstrated that activation of autophagy 
can sustain cell survival after PI3K pan-inhibition. In 
fact, inhibitors that interfere with the autophagic flux 
increased the cytotoxic effects of ZSTK-474. However, 
autophagy activation took place only in some T-ALL 
cell lines, suggesting the influence of a more complex 
cellular background. To address this issue we examined 
the expression of autophagy-related genes. No specific 
expression profiles resulted related to autophagy activation 
or PI3K pan-inhibition and overall gene expression of 
paired samples was similar. Neverthelss, inhibition of 
PI3K specifically modulated a few genes that might 
trigger autophagy. While the Loucy cell line displayed a 
higher autophagy gene expression profile already at basal 
level, we observed the up-regulation of genes involved 
in the autophagic machinery and regulation in all the 
T-ALL cell lines we studied. Increase of these transcripts 
appeared to be cell type-dependent, as ALL-SIL, 
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DND-41 and, partially, Loucy cells, which activated 
autophagy after PI3K pan-inhibition, up-regulated 
numerous genes involved in the formation of 
autophagosomes (DRAM1, GABARAPL1, GABARAPL2, 
MAP1LC3B, ATG16L2, WIPI1, PIK3C3), as well as anti-
apoptotic genes (BCL2) and genes of the unfolded protein 
response signaling (EIF2AK3). Conversely, in Jurkat 
cells, which did not activate autophagy, gene modulation 
was affected to a much lower extent and preferentially 
involved anti-proliferative targets, as the cell cycle 
inhibitor CDKN1B, and the autophagy inhibitor CTSS. 
These observations suggest a role for the PI3K pathway 
in modulating at a transcriptional level the complex 
relationship between pro- and anti-survival signals and 
ultimately the balance between autophagy and apoptosis. 
Of course, more studies are needed to clarify these 
relationships.
In conclusion, we have demonstrated a higher 
efficacy of PI3K pan-inhibition in both PTEN deleted and 
non deleted T-ALL cell lines. Although dual inhibition of 
p110γ/δ PI3K isoforms could be less toxic and reduce side 
effects [25], its efficacy might be limited only to the subset 
of T-ALL patients with ETP-ALL. Moreover, our findings 
shed light about the protective role of autophagy in case 
of PI3K pan-inhibition, supporting the evaluation of 
combining autophagy inhibitors for increasing citotoxicity 
induced by PI3K inhibition. Further investigation will be 
necessary to discriminate the cellular contexts responsible 
for autophagy activation. Addressing this question will 
be critical to select which T-ALL patients may best 
benefit from a therapeutic strategy involving class I PI3K 
inhibition. Indeed, progress in better understanding the 
biology of different T-ALL subtypes should help the 
development of personalized therapy targeted at blocking 
multiple defective signaling pathways of leukemic 
cells [57].
MATERIALS AND METHODS
Cell lines and reagents
Human T-ALL cell lines Jurkat and Loucy (PTEN 
deleted), DND-41 and ALL-SIL (PTEN non deleted) were 
cultured in RPMI-1640 medium (Life Technologies Italia, 
Monza, Italy) supplemented with 10–20% fetal bovine 
serum (Life Technologies), 100 U/ml penicillin and 100 
μg/ml streptomycin (Sigma-Aldrich, Saint Louis, MO, 
USA) at 37°C in a humidified atmosphere of 5% CO2. 
PI3K inhibitors BKM-120, PIK-90, ZSTK-474, A-66, 
TGX-221, AS-605240, CAL-101 and IPI-145, the caspase 
inhibitor z-VAD and the autophagy inhibitor 3-MA, were 
from Selleck Chemicals (Houston TX, USA).
Cell viability assay and cell number count
To test the effects of PI3K inhibitors, T-ALL 
cell lines were cultured for 48 h in the presence of the 
vehicle (DMSO 0.1%) or increasing drug concentrations, 
and cell viability was determined using the MTT [3-(4, 
5-Dimethylthythiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide] cell proliferation kit (Roche Diagnostic, Basel, 
Switzerland), according to manufacturer’s instructions. 
For drug-combination experiments, a combination index 
(CI) number was calculated using the CalcuSyn software 
(Cambridge, UK) based on the Chou and Talalay method 
[58]. CI values between 0.1–0.9 define different grades 
of synergism, values between 0.9–1.1 are additive, 
whereas values > 1.1 are antagonistic. Growth curves 
were generated by counting viable and non-viable cell 
numbers by the Trypan blue dye exclusion method. Cells 
were seeded in 6-well plates, treated with the inhibitors 
(5 μM) or the vehicle alone (DMSO 0.1%) and counted at 
regular intervals up to 72 h. Doubling time was calculated 
with Roth V. 2006 (http://www.doubling-time.com/ 
compute.php).
Flow cytometry analysis of Ki-67 and PIP3
In order to evaluate effects on proliferation, Ki-67 
antigen expression during the different phases of cell 
cycle was evaluated. After 72 h treatment, cells were 
permeabilized with methanol/acetic acid (3:1) and 
incubated with a primary antibody to Ki-67 (Cell 
Signaling Technology, Danvers, MA, USA). Afterwards, 
samples were stained for 1 h with a FITC-conjugated 
secondary antibody (Beckman Coulter, Miami, FL, USA) 
followed by further 20 min incubation with Propidium 
Iodide (PI). To detect PIP3 levels, control (DMSO 0.1%) 
and treated (6 h) cells were fixed in 4% paraformaldehyde 
for 15 min, permeabilized in 0.4% Triton X-100 for 10 
min, washed in PSB 1X with 1% BSA and incubated over 
night at 4°C with a FITC-conjugated anti-PIP3 antibody 
(Echelon Biosciences Inc., Salt Lake City, UT). Analyses 
were performed on an FC500 flow cytometer (Beckman 
Coulter) with the appropriate software (CXP, Beckman 
Coulter).
Annexin V-FITC/PI staining and cell cycle 
analysis
Apoptosis and cell cycle analysis were performed as 
previously described [59]. T-ALL cell lines were treated 
for 48 h with the different compounds (5 μM) or the 
vehicle alone (DMSO 0.1%). Analyses were performed 




Western blotting was performed by standard 
methods, as previously described [60]. Cells were lysed 
using the M-PER Mammalian Protein Extraction Reagent 
supplemented with the Protease and Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific Inc., Rockford, IL, 
USA). The PI3K p110δ antibody was from Santa Cruz 
Biotechnology (Heidelberg, Germany). All other primary 
and secondary antibodies were bought from Cell Signaling 
Technology.
Gene expression analysis
Total RNA was isolated either from control (DMSO 
0.1%) and from 24 h ZSTK-474 treated cells using 
RNeasy Mini Kit (QIAGEN, Valencia, CA) according 
to the manufacturer’s instructions. RNA concentration 
was determined by measuring the absorbance at 260 nm; 
for all samples, the OD 260/OD 280 absorbance ratio 
was of at least 2.0. 3.5 μg of total RNA were reverse-
transcribed into cDNA using the iScriptTM Advanced 
cDNA Syntesis Kit (Bio-rad, Hercules, CA, USA). Gene 
expression of specific autophagy markers was measured 
using the PrimePCRTM Assay for real-time (Bio-rad). For 
each sample, cDNA was mixed with 2x SsoAdvancedTM 
universal supermix (25 ng cDNA/reaction) containing 
SYBR Green (Bio-rad) and aliquoted in equal volumes 
to each well of the real-time PCR arrays. The quantitative 
PCR reaction was performed using a 7300 Real-Time 
PCR system (Applied Biosystems, Foster City, CA, 
USA). The quantitative PCR thermal protocol consisted 
of 95°C for 2 minutes, followed by 40 cycles of 95°C 
for 5 seconds and 60°C for 30 seconds. RLP0 was used 
as control gene and the relative gene expression among 
samples was calculated as 2−∆Ct [61]. These data were then 
subjected to hierarchical clustering using the Spearman’s 
rank correlation metric and the average-linkage method 
and heatmaps were generated using the data analysis tool 
TIGR Multiexperiment Viewer (http://www.tm4.org/) 
[62]. To examine the effects of pan PI3K inhibition in 
the different cell lines, gene expression of the treated cell 
lines was compared with that of untreated control and fold 
change due to the treatment was expressed as 2−∆∆Ct [61]. 
A 2.0-fold change in gene expression was used as the cut-
off threshold.
Statistical analysis
Statistical analyses were performed using Student’s 
t test or one-way ANOVA (Dunnett’s test) at a significance 
level of p < 0.05 (GraphPad Prism Software).
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